Oligonucleotide agonists targeting progranulin
US12203071B2 · kind B2 · utility
0Cited by
6References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 2021 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | May 26, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/346
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.